• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Philip Morris International Inc

    6/3/25 4:06:20 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    FWP 1 tm2516348d4_fwp.htm FWP

    Filed Pursuant to Rule 433

    Registration No. 333-269690

     

    FINAL TERM SHEET

     

    Philip Morris International Inc.

     

    Dated June 3, 2025

     

    2.750% Notes due 2029

    3.250% Notes due 2032

     

    Issuer: Philip Morris International Inc.
       
    Offering Format: SEC Registered
       
    Security: 2.750% Notes due 2029 (the “2029 Notes”)
    3.250% Notes due 2032 (the “2032 Notes”)
       
    Aggregate Principal Amount: 2029 Notes: €500,000,000
    2032 Notes: €500,000,000
       
    Maturity Date: 2029 Notes: June 6, 2029
    2032 Notes: June 6, 2032
       
    Coupon: 2029 Notes: 2.750%
    2032 Notes: 3.250%
       
    Interest Payment Dates: 2029 Notes: Annually on June 6, commencing June 6, 2026
    2032 Notes: Annually on June 6, commencing June 6, 2026
       
    Record Dates: 2029 Notes: May 22
    2032 Notes: May 22
       
    Price to Public: 2029 Notes: 99.482% of principal amount
    2032 Notes: 99.079% of principal amount
       
    Underwriting Discount: 2029 Notes: 0.175% of principal amount
    2032 Notes: 0.225% of principal amount
       
    Net Proceeds: 2029 Notes: €496,535,000 (after the underwriting discount and before expenses)
    2032 Notes: €494,270,000 (after the underwriting discount and before expenses)

     

     

    2

     

    Benchmark Security: 2029 Notes: 0.250% due February 15, 2029
    2032 Notes: 0.000% due February 15, 2032
       
    Benchmark Security Yield: 2029 Notes: 1.897%
    2032 Notes: 2.223%
       
    Spread to Benchmark Security: 2029 Notes: +99.2 basis points
    2032 Notes: +117.7 basis points
       
    Re-Offer Yield: 2029 Notes: 2.889%
    2032 Notes: 3.400%
       
    Mid-Swap Yield: 2029 Notes: 2.089%
    2032 Notes: 2.320%
       
    Spread to Mid-Swap Yield: 2029 Notes: +80 basis points
    2032 Notes: +108 basis points
       
    Optional Redemption:

    2029 Notes:

    Prior to May 6, 2029: Make-whole redemption at Comparable Government Bond Rate plus 15 bps, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.

    On or after May 6, 2029: Redemption at par, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.

     

    2032 Notes:

    Prior to March 6, 2032: Make-whole redemption at Comparable Government Bond Rate plus 20 bps, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.

    On or after March 6, 2032: Redemption at par, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.      

       
    Settlement Date (T+3): June 6, 2025*
       
    Common Code / CUSIP/ ISIN: 2029 Notes: Common Code: 308781259
    CUSIP Number: 718172 DV8
    ISIN Number: XS3087812593
      2032 Notes: Common Code: 308781283
    CUSIP Number: 718172 DW6
    ISIN Number: XS3087812833

     

     

    3

     

    Listing: Application will be made to list the Notes on the New York Stock Exchange      
       
    Joint Book-Running Managers: Barclays Bank PLC
    Goldman Sachs International
    HSBC Continental Europe

     

    Allocations:  2029 Notes   2032 Notes 
    Barclays Bank PLC   166,667,000    166,667,000 
    Goldman Sachs International   166,667,000    166,666,000 
    HSBC Continental Europe   166,666,000    166,667,000 
    Total  €500,000,000   €500,000,000 

     

    * Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the delivery date will be required, by virtue of the fact that the Notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement.

     

    MiFID II and UK MiFIR professionals/ Eligible Counterparties-only/No PRIIPs or UK PRIIPs KID – Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as the Notes are not available to retail investors in the European Economic Area or the United Kingdom.

     

    The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Bank PLC at 1-888-603-5847, Goldman Sachs International at 1-866-471-2526 or HSBC Continental Europe at 1-866-811-8049.

     

     

     

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    SEC Filings

    View All

    SEC Form S-3ASR filed by Philip Morris International Inc

    S-3ASR - Philip Morris International Inc. (0001413329) (Filer)

    2/6/26 4:10:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Philip Morris International Inc

    10-K - Philip Morris International Inc. (0001413329) (Filer)

    2/6/26 7:14:02 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    2/6/26 7:02:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman Calantzopoulos Andre was granted 40,052 shares, increasing direct ownership by 7% to 602,403 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Controller Dobrowolski Reginaldo was granted 6,538 shares, increasing direct ownership by 28% to 26,392 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:27 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group CEO PMI Olczak Jacek was granted 171,039 shares, increasing direct ownership by 31% to 718,465 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/9/26 4:16:51 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International to Present at 2026 CAGNY Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of a presentation by Jacek Olczak, Group CEO PMI, and Emmanuel Babeau, Group Chief Financial Officer, at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 18, 2026, at 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading internati

    2/11/26 8:17:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of 2025 Fourth-Quarter and Full-Year Results

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast on Friday, February 6, 2026, at 9:00 a.m. ET, to discuss its 2025 Fourth-Quarter and Full-Year financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast can be accessed here. The webcast will be hosted by Jacek Olczak, Group CEO PMI, and Emmanuel Babeau, Group Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The we

    1/30/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on January 14, 2026, to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio prim

    12/12/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Presents at 2025 Morgan Stanley Global Consumer & Retail Conference

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, will address investors today at the Morgan Stanley Global Consumer & Retail Conference. The event will be webcast live in listen-only mode here, beginning at approximately 10:15 a.m. ET, and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for six months after the event. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on October 21, 2025, of $7.39 to $7.49. Excluding a total 2025 adjustment of $0.07 per share, this forecast represents a projected increase of 13.5% t

    12/2/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care